EMICIZUMAB DATA
Long-Term Data
The Genentech resource below is a patient-friendly summary of data related to long-term use of emicizumab. This patient-friendly summary includes studies with the strongest and most relevant data and is provided only for educational purposes. You are encouraged to discuss any questions you have about your condition and any current or potential treatments with your healthcare provider.
HEMLIBRA and Long-Term Effectiveness and Safety
Select publications and scientific data presentations with the strongest and most relevant data are shown below.
Safety and Efficacy of Emicizumab in Persons With Hemophilia A With or Without FVIII Inhibitors: Pooled Data From Four Phase III Studies (HAVEN 1–4)
Callaghan MU, Négrier C, Paz-Priel I, et al. Presented at the Virtual ASH Scientific Meeting; December 5–8, 2020.
Long-Term Outcomes With Emicizumab Prophylaxis for Hemophilia A With/Without FVIII Inhibitors From the HAVEN 1-4 Studies
Callaghan MU, Négrier C, Paz-Priel I, et al. Blood. 2021;137:2231-2242.
Long-Term Safety and Efficacy of Emicizumab for up to >5 Years in a Phase 1/2 Study in Patients With Severe Hemophilia A
Shima M, Nagao A, Taki M, et al. Presented at the Virtual ISTH Scientific Meeting; July 12-14, 2020.
Long-term Safety and Efficacy of Emicizumab for up to 5.8 Years and Patients' Perceptions of Symptoms and Daily Life: A Phase 1/2 Study in Patients With Severe Haemophilia A
Shima M, Nagao A, Taki M, et al. Haemophilia 2021;27:81–89.